Alignment Health Plan Earns Top Medicare Advantage Quality Award for 2026
Event summary
- Alignment Health Plan received the 2026 PQA Laura Cranston Excellence in Quality Award for its Medicare Advantage prescription drug (MAPD) plan.
- Only 1.6% of eligible contracts (4 out of 613) achieved this recognition, highlighting the award's exclusivity.
- The award marks the seventh time Alignment has received this distinction, reinforcing its focus on medication safety and adherence.
- Alignment Health achieved perfect 5-star ratings on all five PQA medication measures used in CMS’s star ratings program.
The big picture
Alignment Health’s repeated recognition underscores the growing emphasis on quality and medication safety in the Medicare Advantage market. As CMS continues to refine its star ratings program, plans that prioritize data-driven, personalized care are likely to gain a competitive edge. The award highlights Alignment’s ability to differentiate itself through comprehensive pharmacy initiatives, which are increasingly critical for managing chronic conditions among seniors.
What we're watching
- Sustainability of Quality
- Whether Alignment can maintain its high-quality standards as it expands its national footprint.
- Regulatory Compliance
- How CMS’s evolving star ratings program will impact Alignment’s pharmacy initiatives.
- Competitive Differentiation
- The pace at which Alignment can leverage its data-driven pharmacy initiatives to outperform competitors.